: Immunotherapy against experimental canine visceral leishmaniasi

: Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine. Vaccine 2007,25(33):6176–6190.PubMedCrossRef 18. Bhowmick S, Ravindran R, Ali N: Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy

against visceral leishmaniasis via polarized Th1 response. Vaccine 2007,25(35):6544–6556.PubMedCrossRef 19. Ghose AC, Haldar JP, Pal SC, Mishra BP, Mishra KK: Serological investigations Ibrutinib cell line on Indian kala-azar. Clin Exp Immunol 1980,40(2):318–326.PubMedCentralPubMed 20. Deak E, Jayakumar A, Cho KW, Goldsmith-Pestana K, Dondji B, Lambris JD, McMahon-Pratt D: Murine visceral leishmaniasis: IgM and polyclonal

B-cell activation lead to disease exacerbation. Eur J Immunol 2010,40(5):1355–1368.PubMedCentralPubMedCrossRef 21. Coffman RL, Lebman DA, Rothman P: Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 1993, 54:229–270.PubMedCrossRef 22. Shargh VH, Jaafari MR, Khamesipour A, Jaafari I, Jalali SA, Abbasi A, Badiee A: Liposomal SLA co-incorporated with PO CpG ODNs or CpG ODNs induce the same protection against the murine model of leishmaniasis. Vaccine 2012,30(26):3957–3964.PubMedCrossRef 23. Badiee A, Jaafari MR, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F: Enhancement of immune response and protection in BALB/c mice immunized with R428 in vivo liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition. Colloids Surf B Biointerfaces 2009,74(1):37–44.PubMedCrossRef 24. Cell press Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modabber F, Scott P: Vervet monkeys vaccinated with

killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001,69(1):245–251.PubMedCentralPubMedCrossRef 25. Khalil EAG, Musa AM, Modabber F, El-Hassan AM: Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major plus BCG) in children: an extended phase II study. Ann Trop Paediatr 2006,26(4):357–361.PubMedCrossRef 26. Khalil EAG, Ayed NB, Musa AM, Ibrahim ME, Mukhtar MM, Zijlstra EE, Elhassan IM, Smith PG, Kieny PM, Ghalib HW, et al.: Dichotomy of protective cellular immune responses to human visceral leishmaniasis. Clin Exp Immunol 2005,140(2):349–353.PubMedCentralPubMedCrossRef 27. Nateghi RM, Keshavarz H, Khamesipour A: Immune response of BALB/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major (Alum-ALM) mixed with BCG or Mycobacterium vaccae. Trop Biomed 2010,27(1):89–102. 28.

Comments are closed.